oc000253
10.3205/oc000253
urn:nbn:de:0183-oc0002533
Case Report
Shield ulcer in keratoconus in the absence of atopic or vernal kerato-conjunctivitis
Niestrata
Niestrata
Magdalena
M
Department of Ophthalmology, Queen’s Hospital, Romford, United Kingdom
author
Kohli
Kohli
Shuchi
S
Department of Ophthalmology, Queen’s Hospital, Romford, United Kingdom
author
Saleki
Saleki
Mohammad
M
Department of Ophthalmology, Queen’s Hospital, Romford, United Kingdom
author
Ashena
Ashena
Zahra
Z
Department of Ophthalmology, Queen’s Hospital, Rom Valley Way, Romford RM7 0AG, United KingdomDepartment of Ophthalmology, Queen’s Hospital, Romford, United Kingdom
zashena@nhs.net
author
German Medical Science GMS Publishing House
Düsseldorf
610
20250612
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
2193-1496
15
GMS Ophthalmology Cases
GMS Ophthalmol Cases
05
Corneal shield ulcer is a severe complication of atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC). This condition is caused by the mechanical irritation of the corneal epithelium due to giant papillae and toxic epitheliopathy resulting from inflammatory mediators. To date, there have been no reported cases of corneal shield ulcers in the literature without AKC or VKC. However, the authors have reported a unique case of shield ulcer in a patient with keratoconus but no history of AKC or VKC. The cause is hypothesised to be due to mechanical friction between the corneal steep apex and palpebral conjunctiva. Additionally, a new technique, the use of a dry amniotic membrane, is described to manage the persistent epithelial defect in shield ulcers.
IntroductionCorneal shield ulcer is a complication of atopic and vernal keratoconjunctivitis, occurring in approximately 3–11% of patients with vernal keratoconjunctivitis (VKC), which causes significant morbidity and challenges to treatment , . They appear as shallow greyish indolent ulcers usually located in the superior part of the cornea. The pathophysiology of corneal shield ulcers is thought to have a mechanical and inflammatory or chemical component. The mechanical friction of the sub-tarsal giant papillae causes micro-abrasions on the cornea . This is coupled with active inflammation caused by chemical mediators released by eosinophils, which have cytotoxic properties and prevent epithelial healing, leading to the development of recurrent epithelial micro-erosion, adherence of mucus to the plaque and subsequent deposition of calcium in the plaque, which further prevents re-epithelialization . Microscopy of the plaque has demonstrated collagen fibrils extending from the Bowman’s layer into the deep layers of the plaque and toxic eosinophilic granule protein in the inflammatory debris of patients with shield ulcer .Treatment of shield ulcers ranges from topical and systemic medical therapy to surgical debridement of the plaque to promote re-epithelialization, depending on the severity of the ulcers .In the literature, shield ulcers have been described solely in association with VKC and atopic keratoconjunctivitis (AKC), and no reports exist of its presence without these associations . The authors have reported a case of a shield ulcer in a patient with keratoconus, without any allergic or atopic eye disease. They have hypothesised that the possible cause, in this case, may be due to the mechanical friction between the corneal apex and palpebral conjunctiva in a steep ectatic cornea, which triggers the formation of epithelial micro-erosions and calcium deposition, ultimately resulting in a calcific shield ulcer.Furthermore, the authors present successful management of this condition with a novel treatment modality – a dry patch of amniotic membrane with a very good visual outcome.
Case descriptionA 38-year-old Caribbean male, who had bilateral keratoconus and underwent left eye epithelium-off corneal crosslinking, using the Dresden protocol 10 years ago, presented with a one-month history of discomfort in the left eye, photosensitivity, and reduced vision. The patient’s left eye was his only functional eye due to severe vision impairment in the other eye caused by advanced keratoconus with a maximum keratometry of 79 D. He could not tolerate rigid gas-permeable contact lenses and had discontinued follow-ups for ten years. The patient had no medical history of asthma, eczema, or hay fever and denied experiencing symptoms of itchy eyes or habitual eye rubbing.On examination, the best corrected visual acuity (BCVA) with glasses was counting fingers in the right and 1.06 LogMAR in the left eye. The slit lamp examination showed a distinctive calcified shield ulcer, measuring 3 mm x 2<![CDATA[.8 mm</PlainText></TextGroup>, on the paracentral cornea, with significant stromal thinning, no associated corneal neovascularization or any signs of allergic eye disease, i.e. limbal Horner-Trantas dots or palpebral micro/macro-papillae (<TextGroup><PlainText>Figure 1 </PlainText></TextGroup><ImgLink imgNo="1" imgType="figure" />, Figure 2 <ImgLink imgNo="2" imgType="figure" />, Figure 3 <ImgLink imgNo="3" imgType="figure" />).</Pgraph><Pgraph>The corneal sensation was intact. The fellow eye showed advanced keratoconus with mild apical scarring and Vogt striae and no features of allergic eye disease.</Pgraph><Pgraph>The calcific deposition was partially debrided at the slit lamp and treatment with topical preservative-free Dexamethasone 0.1% and preservative-free Chloramphenicol 0.5% was commenced. A further attempt to debride the residual calcific plaque was abandoned due to the extreme stromal thinning and the risk of corneal perforation. Despite there being no reported underlying health issues, blood tests were conducted and all results returned normal, ruling out hypercalcemia.</Pgraph><Pgraph>At two weeks follow-up, the patient remained symptomatic with continuing pain, photosensitivity and reduced vision. The cornea showed a persistent epithelial defect, measuring 2.7 mm x 2.5 mm, with a surrounding residue of plaque. Figure 4 <ImgLink imgNo="4" imgType="figure" /> shows partially resected calcific plaque, with persistent epithelial defect surrounded by raised margin, which prevented migration of epithelial cells from the limbus to the defect. Fluorescein staining confirmed a persistent epithelial defect in the paracentral cornea (Figure 5 <ImgLink imgNo="5" imgType="figure" />).</Pgraph><Pgraph>The treatment was continued by adding preservative-free lubricating drops every two hours, and surgical debridement of the calcific plaque was planned. He underwent surgical excision of the calcific plaque and 36<TextGroup><PlainText>0 d</PlainText></TextGroup>egree removal of the raised margin surrounding the bare stroma, using a crescent blade. Also, to facilitate epithelialization, a dry amniotic membrane disc of 12 mm diameter was placed on the cornea (epithelial side f) <TextGroup><PlainText>and secured with</PlainText></TextGroup> a bandage contact lens (video in <TextGroup><PlainText>Attachment 1 </PlainText></TextGroup><AttachmentLink attachmentNo="1" />). The amniotic membrane used was produced by Omnigen<Superscript>®</Superscript>, who generate their membrane from consented mothers having planned caesarean sections.</Pgraph><Pgraph>One week post-operatively, the symptoms were improved, and the eye was comfortable. Examination showed a quiet eye with partially disintegrated amniotic membrane with a paracentral faint scar (Figure 6 <ImgLink imgNo="6" imgType="figure" />).</Pgraph><Pgraph>Three weeks later, the bandage contact lens was removed, the epithelial defect was entirely closed, and the corneal stroma was healed with minimal residual scarring (Figure 7 <ImgLink imgNo="7" imgType="figure" />).</Pgraph><Pgraph>The unaided visual acuity in the affected eye improved to 0.66 LogMAR, further improving to 0.4 LogMAR with pinhole. The anterior segment optical coherence tomography (OCT) showed a significant posterior ectasia, paracentral stromal thinning (white arrow) (233 µm) with associated epithelial hypertrophy (yellow arrow) (92 µm) to mask the stromal thinning and irregularity (Figure 8 <ImgLink imgNo="8" imgType="figure" />), and Pentacam revealed maximum keratometry of 5<TextGroup><PlainText>7.3 D</PlainText></TextGroup>.</Pgraph><Pgraph>Three months post-operatively, no recurrence of the plaque was noted, and the best spectacle-corrected visual acuity in the left eye was 0.3 LogMAR.</Pgraph><Pgraph></Pgraph></TextBlock>
<TextBlock name="Discussion" linked="yes">
<MainHeadline>Discussion</MainHeadline><Pgraph>The present study comprises the first report of a calcific shield ulcer without AKC or VKC. This highlights the possibility of an alternative or additional element in the pathogenesis of shield ulcers in the absence of active inflammation, like potential friction between the palpebral conjunctiva and the ectatic corneal apex, which is often aggravated by eye rubbing, triggering the formation of epithelial micro-erosions and calcium deposition and resulting in the development of a calcific shield ulcer at the corneal apex, contrary to the conventional superior corneal shield ulcer. Given the thin epithelium over the cone in keratoconus patients <TextLink reference="7"></TextLink>, microabrasion is, theoretically, more expected in these eyes than in eyes with normal epithelial thickness. Nevertheless, mechanical friction cannot be the sole trigger for the development of shield ulcers since no similar ulcers have been reported in keratoconus patients so far. This stresses the importance of corneal surface protection in patients with corneal ectasias, irrespective of the absence of allergic eye disease.</Pgraph><Pgraph>Medical therapy includes a combination of topical anti-allergy and anti-inflammatory medication such as mast cell stabilisers, non-steroidal agents, corticosteroids and cyclosporin <TextLink reference="3"></TextLink>, topical antibiotics to prevent or treat secondary bacterial infection and lubricating drops, topical tacrolimus in refractory VKC <TextLink reference="8"></TextLink>, supratarsal injection of corticosteroids <TextLink reference="9"></TextLink> or systemic immunosuppression <TextLink reference="10"></TextLink>. In cases of non-healing shield ulcers despite adequate medical therapy, surgical interventions including temporary tarsorrhaphy <TextLink reference="11"></TextLink>, phototherapeutic keratectomy <TextLink reference="12"></TextLink> and superficial keratectomy <TextLink reference="4"></TextLink> are beneficial to achieve re-epithelialization. Moreover, a few studies have described successful use of amniotic membrane transplantation (AMT) to aid re-epithelialization in non-healing shield ulcers following debridement <TextLink reference="13"></TextLink>, <TextLink reference="14"></TextLink>.</Pgraph><Pgraph>Table 1 <ImgLink imgNo="1" imgType="table" /> summarises two large case series on the management of shield ulcers. The majority of Grade 1 and 2 ulcers re-epithelialize with medical therapy alone <TextLink reference="6"></TextLink>, while out of all Grade 3 ulcers, only 1.7% achieved closure with medical therapy alone, as opposed to 100% re-epithelialization rate in eyes treated with surgical debridement and AMT <TextLink reference="6"></TextLink>.</Pgraph><Pgraph>Amniotic membrane facilitates corneal healing by reinforcing the adhesion between basal epithelial cells and enabling epithelial migration. In addition, it reduces scar formation by suppressing transforming growth factor B and the proliferation and differentiation of myofibroblasts in normal corneas <TextLink reference="15"></TextLink>.</Pgraph><Pgraph>Furthermore, the amniotic membrane reduces the inflammatory reaction by forming a protective barrier between the ocular surface and the tear film containing proinflammatory mediators <TextLink reference="15"></TextLink>. However, fresh AMT is not readily available and requires a surgical theatre, which can delay treatment. Furthermore, it needs to be secured on the cornea with sutures, which carries suture related risk of infection <TextLink reference="16"></TextLink>. </Pgraph><Pgraph>In the presented case, the patient with a Grade 3 ulcer was treated with superficial keratectomy, in addition to medical treatment, in line with the literature evidence.</Pgraph><Pgraph>This is the first report of the use of a dry amniotic membrane, secured with a bandage contact lens, for the management of a non-healing shield ulcer. The amnion was absorbed within 2–3 weeks, following which the contact lens was removed. This new technology permitting, outpatient application of amniotic membrane on a cornea offers ample opportunities in the management of epitheliopathies refractive to medical treatment and nonhealing epithelial defects. Efficacy of dried amniotic membrane on healing persistent epithelial defect secondary to neurotrophic cornea, post-keratoplasty, severe dry eye, limbal stem cell deficiency due to Stevens-Johnson syndrome, glaucoma procedures, graft-versus-host disease and severe allergic reaction and infectious keratitis has been demonstrated <TextLink reference="17"></TextLink>.</Pgraph><Pgraph>Our patient achieved a significant improvement in visual acuity from LogMAR 1.06 to 0.3, which is better than the post-treatment visual acuity reported before <TextLink reference="6"></TextLink>. This may be the consequence of the absence of an allergic inflammatory component in the presented case or of prompt surgical intervention with debridement and amniotic membrane use, which the authors advocate.</Pgraph></TextBlock>
<TextBlock name="Conclusion" linked="yes">
<MainHeadline>Conclusion</MainHeadline><Pgraph>Previously, shield ulcers have been exclusively reported in eyes with a history of AKC and VCK. We described a case of calcific shield ulcer in a patient with keratoconus without giant papillae or previous AKC/VKC, highlighting the potential for other contributing pathophysiological factors, like friction between the conjunctiva and a steep cornea. Based on our report, significant improvement in visual acuity is achievable with prompt surgical intervention and application of amniotic membrane in shield ulcers with persistent epithelial defects. Dry amniotic membrane provides an excellent alternative to conventional amniotic membrane transplantation in non-healing epitheliopathy with easy application and the possibility to use in the outpatient setting.</Pgraph></TextBlock>
<TextBlock name="Notes" linked="yes">
<MainHeadline>Notes</MainHeadline><SubHeadline>Video attachment</SubHeadline><Pgraph>For a video of the surgical debridement of the shield ulcer’s calcified edge and insertion of dry amniotic membrane, see Attachment 1 <AttachmentLink attachmentNo="1" />.</Pgraph><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock>
<References linked="yes">
<Reference refNo="1">
<RefAuthor>Das S</RefAuthor>
<RefTitle>Shield ulcer: A very rare presentation</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Kerala J Ophthalmol</RefJournal>
<RefPage>244-6</RefPage>
<RefTotal>Das S. Shield ulcer: A very rare presentation. Kerala J Ophthalmol. 2017;29(3):244-6. DOI: 10.4103/kjo.kjo_73_17 </RefTotal>
<RefLink>https://doi.org/10.4103/kjo.kjo_73_17</RefLink>
</Reference>
<Reference refNo="2">
<RefAuthor>Bonini S</RefAuthor>
<RefAuthor>Bonini S</RefAuthor>
<RefAuthor>Lambiase A</RefAuthor>
<RefAuthor>Marchi S</RefAuthor>
<RefAuthor>Pasqualetti P</RefAuthor>
<RefAuthor>Zuccaro O</RefAuthor>
<RefAuthor>Rama P</RefAuthor>
<RefAuthor>Magrini L</RefAuthor>
<RefAuthor>Juhas T</RefAuthor>
<RefAuthor>Bucci MG</RefAuthor>
<RefTitle>Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup</RefTitle>
<RefYear>2000</RefYear>
<RefJournal>Ophthalmology</RefJournal>
<RefPage>1157-63</RefPage>
<RefTotal>Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, Rama P, Magrini L, Juhas T, Bucci MG. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000 Jun;107(6):1157-63. DOI: 10.1016/s0161-6420(00)00092-0</RefTotal>
<RefLink>https://doi.org/10.1016/s0161-6420(00)00092-0</RefLink>
</Reference>
<Reference refNo="3">
<RefAuthor>Singhal D</RefAuthor>
<RefAuthor>Sahay P</RefAuthor>
<RefAuthor>Maharana PK</RefAuthor>
<RefAuthor>Raj N</RefAuthor>
<RefAuthor>Sharma N</RefAuthor>
<RefAuthor>Titiyal JS</RefAuthor>
<RefTitle>Vernal Keratoconjunctivitis</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Surv Ophthalmol</RefJournal>
<RefPage>289-311</RefPage>
<RefTotal>Singhal D, Sahay P, Maharana PK, Raj N, Sharma N, Titiyal JS. Vernal Keratoconjunctivitis. Surv Ophthalmol. 2019;64(3):289-311. DOI: 10.1016/j.survophthal.2018.12.001</RefTotal>
<RefLink>https://doi.org/10.1016/j.survophthal.2018.12.001</RefLink>
</Reference>
<Reference refNo="4">
<RefAuthor>Cameron JA</RefAuthor>
<RefTitle>Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis</RefTitle>
<RefYear>1995</RefYear>
<RefJournal>Ophthalmology</RefJournal>
<RefPage>985-93</RefPage>
<RefTotal>Cameron JA. Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. Ophthalmology. 1995 Jun;102(6):985-93. DOI: 10.1016/s0161-6420(95)30925-6</RefTotal>
<RefLink>https://doi.org/10.1016/s0161-6420(95)30925-6</RefLink>
</Reference>
<Reference refNo="5">
<RefAuthor>Udell IJ</RefAuthor>
<RefAuthor>Gleich GJ</RefAuthor>
<RefAuthor>Allansmith MR</RefAuthor>
<RefAuthor>Ackerman SJ</RefAuthor>
<RefAuthor>Abelson MB</RefAuthor>
<RefTitle>Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears</RefTitle>
<RefYear>1981</RefYear>
<RefJournal>Am J Ophthalmol</RefJournal>
<RefPage>824-8</RefPage>
<RefTotal>Udell IJ, Gleich GJ, Allansmith MR, Ackerman SJ, Abelson MB. Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears. Am J Ophthalmol. 1981 Dec;92(6):824-8. DOI: 10.1016/s0002-9394(14)75637-5</RefTotal>
<RefLink>https://doi.org/10.1016/s0002-9394(14)75637-5</RefLink>
</Reference>
<Reference refNo="6">
<RefAuthor>Reddy JC</RefAuthor>
<RefAuthor>Basu S</RefAuthor>
<RefAuthor>Saboo US</RefAuthor>
<RefAuthor>Murthy SI</RefAuthor>
<RefAuthor>Vaddavalli PK</RefAuthor>
<RefAuthor>Sangwan VS</RefAuthor>
<RefTitle>Management, clinical outcomes, and complications of shield ulcers in vernal keratoconjunctivitis</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Am J Ophthalmol</RefJournal>
<RefPage>550-559.e1</RefPage>
<RefTotal>Reddy JC, Basu S, Saboo US, Murthy SI, Vaddavalli PK, Sangwan VS. Management, clinical outcomes, and complications of shield ulcers in vernal keratoconjunctivitis. Am J Ophthalmol. 2013 Mar;155(3):550-559.e1. DOI: 10.1016/j.ajo.2012.09.014</RefTotal>
<RefLink>https://doi.org/10.1016/j.ajo.2012.09.014</RefLink>
</Reference>
<Reference refNo="7">
<RefAuthor>Reinstein DZ</RefAuthor>
<RefAuthor>Archer TJ</RefAuthor>
<RefAuthor>Gobbe M</RefAuthor>
<RefTitle>Corneal epithelial thickness profile in the diagnosis of keratoconus</RefTitle>
<RefYear>2009</RefYear>
<RefJournal>J Refract Surg</RefJournal>
<RefPage>604-10</RefPage>
<RefTotal>Reinstein DZ, Archer TJ, Gobbe M. Corneal epithelial thickness profile in the diagnosis of keratoconus. J Refract Surg. 2009 Jul;25(7):604-10. DOI: 10.3928/1081597X-20090610-06</RefTotal>
<RefLink>https://doi.org/10.3928/1081597X-20090610-06</RefLink>
</Reference>
<Reference refNo="8">
<RefAuthor>Liu FY</RefAuthor>
<RefAuthor>Liu HY</RefAuthor>
<RefAuthor>Chu HS</RefAuthor>
<RefAuthor>Chen WL</RefAuthor>
<RefAuthor>Hu FR</RefAuthor>
<RefAuthor>Wang IJ</RefAuthor>
<RefTitle>Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Graefes Arch Clin Exp Ophthalmol</RefJournal>
<RefPage>967-74</RefPage>
<RefTotal>Liu FY, Liu HY, Chu HS, Chen WL, Hu FR, Wang IJ. Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):967-74. DOI: 10.1007/s00417-019-04287-1</RefTotal>
<RefLink>https://doi.org/10.1007/s00417-019-04287-1</RefLink>
</Reference>
<Reference refNo="9">
<RefAuthor>Holsclaw DS</RefAuthor>
<RefAuthor>Whitcher JP</RefAuthor>
<RefAuthor>Wong IG</RefAuthor>
<RefAuthor>Margolis TP</RefAuthor>
<RefTitle>Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis</RefTitle>
<RefYear>1996</RefYear>
<RefJournal>Am J Ophthalmol</RefJournal>
<RefPage>243-9</RefPage>
<RefTotal>Holsclaw DS, Whitcher JP, Wong IG, Margolis TP. Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol. 1996 Mar;121(3):243-9. DOI: 10.1016/s0002-9394(14)70271-5</RefTotal>
<RefLink>https://doi.org/10.1016/s0002-9394(14)70271-5</RefLink>
</Reference>
<Reference refNo="10">
<RefAuthor>Buckley RJ</RefAuthor>
<RefTitle>Vernal keratopathy and its management</RefTitle>
<RefYear>1981</RefYear>
<RefJournal>Trans Ophthalmol Soc U K (1962)</RefJournal>
<RefPage>234-8</RefPage>
<RefTotal>Buckley RJ. Vernal keratopathy and its management. Trans Ophthalmol Soc U K (1962). 1981;101 (Pt 2):234-8.</RefTotal>
</Reference>
<Reference refNo="11">
<RefAuthor>Jones B</RefAuthor>
<RefTitle>Vernal keratitis</RefTitle>
<RefYear>1961</RefYear>
<RefJournal>Trans Ophthalmol Soc UK</RefJournal>
<RefPage>215-28</RefPage>
<RefTotal>Jones B. Vernal keratitis. Trans Ophthalmol Soc UK. 1961;81:215-28.</RefTotal>
</Reference>
<Reference refNo="12">
<RefAuthor>Cameron JA</RefAuthor>
<RefAuthor>Antonios SR</RefAuthor>
<RefAuthor>Badr IA</RefAuthor>
<RefTitle>Excimer laser phototherapeutic keratectomy for shield ulcers and corneal plaques in vernal keratoconjunctivitis</RefTitle>
<RefYear>1995</RefYear>
<RefJournal>J Refract Surg</RefJournal>
<RefPage>31-5</RefPage>
<RefTotal>Cameron JA, Antonios SR, Badr IA. Excimer laser phototherapeutic keratectomy for shield ulcers and corneal plaques in vernal keratoconjunctivitis. J Refract Surg. 1995;11(1):31-5. DOI: 10.3928/1081-597X-19950101-09</RefTotal>
<RefLink>https://doi.org/10.3928/1081-597X-19950101-09</RefLink>
</Reference>
<Reference refNo="13">
<RefAuthor>Rouher N</RefAuthor>
<RefAuthor>Pilon F</RefAuthor>
<RefAuthor>Dalens H</RefAuthor>
<RefAuthor>Fauquert JL</RefAuthor>
<RefAuthor>Kemeny JL</RefAuthor>
<RefAuthor>Rigal D</RefAuthor>
<RefAuthor>Chiambaretta F</RefAuthor>
<RefTitle>Greffe de membrane amniotique et traitement des ulcères de cornée lors des kératoconjonctivites chroniques allergiques</RefTitle>
<RefYear>2004</RefYear>
<RefJournal>J Fr Ophtalmol</RefJournal>
<RefPage>1091-7</RefPage>
<RefTotal>Rouher N, Pilon F, Dalens H, Fauquert JL, Kemeny JL, Rigal D, Chiambaretta F. Greffe de membrane amniotique et traitement des ulcères de cornée lors des kératoconjonctivites chroniques allergiques [Implantation of preserved human amniotic membrane for the treatment of shield ulcers and persistent corneal epithelial defects in chronic allergic keratoconjunctivitis]. J Fr Ophtalmol. 2004 Dec;27(10):1091-7. DOI: 10.1016/s0181-5512(04)96277-8</RefTotal>
<RefLink>https://doi.org/10.1016/s0181-5512(04)96277-8</RefLink>
</Reference>
<Reference refNo="14">
<RefAuthor>Lin HY</RefAuthor>
<RefAuthor>Yeh PT</RefAuthor>
<RefAuthor>Shiao CS</RefAuthor>
<RefAuthor>Hu FR</RefAuthor>
<RefTitle>Surgical management and immunohistochemical study of corneal plaques in vernal keratoconjunctivitis</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>J Formos Med Assoc</RefJournal>
<RefPage>569-73</RefPage>
<RefTotal>Lin HY, Yeh PT, Shiao CS, Hu FR. Surgical management and immunohistochemical study of corneal plaques in vernal keratoconjunctivitis. J Formos Med Assoc. 2013 Sep;112(9):569-73. DOI: 10.1016/j.jfma.2012.07.017</RefTotal>
<RefLink>https://doi.org/10.1016/j.jfma.2012.07.017</RefLink>
</Reference>
<Reference refNo="15">
<RefAuthor>Sangwan VS</RefAuthor>
<RefAuthor>Tseng SC</RefAuthor>
<RefTitle>New perspectives in ocular surface disorders. An integrated approach for diagnosis and management</RefTitle>
<RefYear>2001</RefYear>
<RefJournal>Indian J Ophthalmol</RefJournal>
<RefPage>153-68</RefPage>
<RefTotal>Sangwan VS, Tseng SC. New perspectives in ocular surface disorders. An integrated approach for diagnosis and management. Indian J Ophthalmol. 2001 Sep;49(3):153-68.</RefTotal>
</Reference>
<Reference refNo="16">
<RefAuthor>Prasad A</RefAuthor>
<RefAuthor>Jain S</RefAuthor>
<RefTitle>Amniotic membrane transplantation for treatment of refractory giant papillae and Shield ulcer in vernal keratoconjunctivitis</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>Invest Ophthalmol Vis Sci</RefJournal>
<RefPage>423</RefPage>
<RefTotal>Prasad A, Jain S. Amniotic membrane transplantation for treatment of refractory giant papillae and Shield ulcer in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2020;61(7):423.</RefTotal>
</Reference>
<Reference refNo="17">
<RefAuthor>Maqsood S</RefAuthor>
<RefAuthor>Elsawah K</RefAuthor>
<RefAuthor>Dhillon N</RefAuthor>
<RefAuthor>Soliman S</RefAuthor>
<RefAuthor>Laginaf M</RefAuthor>
<RefAuthor>Lodhia V</RefAuthor>
<RefAuthor>Lake D</RefAuthor>
<RefAuthor>Hamada S</RefAuthor>
<RefAuthor>Elalfy M</RefAuthor>
<RefTitle>Management of Persistent Corneal Epithelial Defects with Human Amniotic Membrane-derived Dry Matrix</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Clin Ophthalmol</RefJournal>
<RefPage>2231-8</RefPage>
<RefTotal>Maqsood S, Elsawah K, Dhillon N, Soliman S, Laginaf M, Lodhia V, Lake D, Hamada S, Elalfy M. Management of Persistent Corneal Epithelial Defects with Human Amniotic Membrane-derived Dry Matrix. Clin Ophthalmol. 2021;15:2231-8. DOI: 10.2147/OPTH.S299141</RefTotal>
<RefLink>https://doi.org/10.2147/OPTH.S299141</RefLink>
</Reference>
</References>
<Media>
<Tables>
<Table format="png">
<MediaNo>1</MediaNo>
<MediaID>1</MediaID>
<Caption><Pgraph><Mark1>Table 1: The two large retrospective case series on the management and outcome of shield ulcers</Mark1></Pgraph></Caption>
</Table>
<NoOfTables>1</NoOfTables>
</Tables>
<Figures>
<Figure width="512" height="468" format="png">
<MediaNo>1</MediaNo>
<MediaID>1</MediaID>
<Caption><Pgraph><Mark1>Figure 1: Calcified shield ulcer measuring 3 mm by 2.8 mm affecting the paracentral cornea</Mark1></Pgraph></Caption>
</Figure>
<Figure width="512" height="448" format="png">
<MediaNo>2</MediaNo>
<MediaID>2</MediaID>
<Caption><Pgraph><Mark1>Figure 2: Lower tarsal conjunctiva, with no evidence of papillary reaction</Mark1></Pgraph></Caption>
</Figure>
<Figure width="512" height="470" format="png">
<MediaNo>3</MediaNo>
<MediaID>3</MediaID>
<Caption><Pgraph><Mark1>Figure 3: Upper tarsal conjunctiva with no giant papillae</Mark1></Pgraph></Caption>
</Figure>
<Figure width="512" height="436" format="png">
<MediaNo>4</MediaNo>
<MediaID>4</MediaID>
<Caption><Pgraph><Mark1>Figure 4: Partially removed calcific deposit and corresponding corneal epithelial defect</Mark1></Pgraph></Caption>
</Figure>
<Figure width="512" height="416" format="png">
<MediaNo>5</MediaNo>
<MediaID>5</MediaID>
<Caption><Pgraph><Mark1>Figure 5: Persistent corneal epithelial defect, two weeks after partial removal of the calcific membrane and starting the medications</Mark1></Pgraph></Caption>
</Figure>
<Figure width="512" height="440" format="png">
<MediaNo>6</MediaNo>
<MediaID>6</MediaID>
<Caption><Pgraph><Mark1>Figure 6: Left cornea 2 weeks post-operatively. The amnion has almost absorbed, and the bandage contact lens is in place.</Mark1></Pgraph></Caption>
</Figure>
<Figure width="512" height="430" format="png">
<MediaNo>7</MediaNo>
<MediaID>7</MediaID>
<Caption><Pgraph><Mark1>Figure 7: Left cornea 3 weeks post-operatively. The amniotic membrane has fully absorbed, and the bandage contact lens is removed. A faint scar is visible in the paracentral cornea.</Mark1></Pgraph></Caption>
</Figure>
<Figure width="640" height="220" format="png">
<MediaNo>8</MediaNo>
<MediaID>8</MediaID>
<Caption><Pgraph><Mark1>Figure 8: Anterior segment OCT of the left cornea 3 weeks post-operatively shows significant posterior elevation, apical stromal thinning (white arrow) (325 µm) and epithelial hypertrophy (yellow arrow) (92 µm) following surface healing.</Mark1></Pgraph></Caption>
</Figure>
<NoOfPictures>8</NoOfPictures>
</Figures>
<InlineFigures>
<NoOfPictures>0</NoOfPictures>
</InlineFigures>
<Attachments>
<Attachment>
<MediaNo>1</MediaNo>
<MediaID mimeType="video/quicktime" size="44117594" filename="oc000253.a1.mov" url="" origFilename="oc000253_Attachment1.mov">1</MediaID>
<AttachmentTitle>Surgical debridement of the shield ulcer’s calcified edge and insertion of dry amniotic membrane</AttachmentTitle>
</Attachment>
<NoOfAttachments>1</NoOfAttachments>
</Attachments>
</Media>
</OrigData>
</GmsArticle>]]></plaintext></textgroup></pgraph></textblock></origdata></gmsarticle>